Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Acta Academiae Medicinae Qingdao Universitatis》 2009-03
Add to Favorite Get Latest Update


LIU ZHU-ZHEN,YANG JIE,WANG HONG-YI,et al (Department of Hematology,The Affiliated Hospital of Qingdao University Medical College,Qingdao 266003,China)  
Objective To observe the serum levels of IL-6 and TNF-α in patients with multiple myeloma(MM),and explore the effects of thalidomide-combination chemotherapy on IL-6 and TNF-α.Methods The serum IL-6 and TNF-α in 79 MM patients and 30 normal controls were determined by ELISA,and the results of the patients in different stages as well as before and after therapy were compared.Results The concentrations of IL-6 and TNF-α in MM group were significantly higher than those in the control(t=8.117,11.525;P0.001).The levels of IL-6 and TNF-α in stage Ⅲ and stage Ⅱpatients were higher than those of stageⅠ(F=4.233,10.273;q=3.012-6.294;P0.05).Of 55 patients responding well to the therapy,levels of IL-6 and TNF-α declined significantly compared with before treatment(t=3.153,4.361;P0.01),for 22 patients who showed poor response to the therapy,the serum parameters did not reveal significant difference from that of before medication(t=0.850,0.913;P0.05).Conclusion The concentrations of IL-6 and TNF-α are high in MM patients,and associated with the clinical stages of the disease.The thalidomide-combined chemotherapy can significantly reduce the serum levels of IL-6 and TNF-α,a detection of this two items can be used as an auxiliary index in estimating the therapeutic efficacy and the condition of patients with MM.
【CateGory Index】: R733.3
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved